MAPT and Alzheimer disease: Ongoing clinical trials have aimed at the development of new effective therapeutic options for NDs, particularly AD, which includes a broad spectrum of different agents, including immunotherapy against amyloid beta, tau protein, tau inhibitors, and anti-neuroinflammatory agents.